GlassScriptPhysician profile
Darin A Harden
NPI 1194702381
$11,530.92
in general payments reported to CMS, 2019-2025
47 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.07 · 2020: $94.29 · 2021: $2,591 · 2022: $1,778 · 2023: $1,990 · 2024: $3,020 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,055.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,041.76 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $971.31 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $820.93 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $586.69 | 2021-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $547.38 | 2023-2025 | Auvelity, Sunosi |
| Biohaven Pharmaceuticals, INC. | $492.23 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $484.05 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $448.69 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $395.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lilly USA, LLC | $260.34 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Tris Pharma INC | $249.42 | 2023-2025 | Dyanavel Xr |
| Amgen INC. | $220.25 | 2019-2024 | Otezla, Repatha |
| Neurocrine Biosciences, INC. | $219.43 | 2022-2025 | Ingrezza |
| Pfizer INC. | $215.77 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $183.15 | 2021-2023 | Contrave, Onzetra Xsail, Nexlizet |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $181.92 | 2023-2025 | |
| Esperion Therapeutics, INC. | $174.66 | 2021-2022 | |
| Lundbeck LLC | $156.50 | 2022-2025 | Rexulti |
| Indivior INC. | $155.94 | 2022-2025 | Sublocade, Perseris |
| Astrazeneca Pharmaceuticals LP | $152.93 | 2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $140.22 | 2021-2023 | Trelegy Ellipta |
| Uswm, LLC | $139.92 | 2022-2024 | Lucemyra, Zimhi |
| Phathom Pharmaceuticals, INC. | $135.52 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $131.86 | 2022 | |
| Alkermes, INC. | $115.87 | 2021-2025 | Aristada, Lybalvi |
| Boston Scientific Corporation | $111.43 | 2021 | |
| Corcept Therapeutics | $100.51 | 2025 | Korlym |
| Allergan, INC. | $74.03 | 2020 | |
| Novo Nordisk INC | $71.95 | 2021-2025 | Rybelsus, Ozempic |
| Averitas Pharma INC. | $60.88 | 2023 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $54.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $52.81 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $47.69 | 2025 | Xelstrym, Secuado |
| Gilead Sciences, INC. | $40.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.62 | 2023 | Trintellix |
| Almatica Pharma LLC | $36.59 | 2024 | Loreev Xr |
| Abbott Laboratories | $36.08 | 2022-2024 | Freestyle Libre 3 |
| Cipher Pharmaceuticals US LLC | $35.83 | 2025 | Spinosad, Natroba |
| Bioxcel Therapeutics, INC. | $25.00 | 2023 | Igalmi |
| Collegium Pharmaceutical, INC. | $20.62 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $18.47 | 2022 | |
| Medtronic, INC. | $15.86 | 2025 | Minimed 780g |
| Shield Therapeutics INC | $15.30 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2021 | |
| Exact Sciences Corporation | $13.65 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $12.93 | 2022 | |
| Amarin Pharma, INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Harden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.